BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12144581)

  • 1. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
    Nzeako UC; Murray JA
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
    Katz PO; Anderson C; Khoury R; Castell DO
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
    Katz PO; Hatlebakk JG; Castell DO
    Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
    Franco MT; Salvia G; Terrin G; Spadaro R; De Rosa I; Iula VD; Cucchiara S
    Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
    Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors.
    Fouad YM; Katz PO; Castell DO
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1467-71. PubMed ID: 10571603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M; Burnham WR; Kamm MA
    Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
    Gardner JD; Gallo-Torres H; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Nov; 18(9):891-905. PubMed ID: 14616153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
    Frazzoni M; De Micheli E; Grisendi A; Savarino V
    Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
    Peghini PL; Katz PO; Bracy NA; Castell DO
    Am J Gastroenterol; 1998 May; 93(5):763-7. PubMed ID: 9625124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
    Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
    Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
    Hinder RA
    Dig Liver Dis; 2002 Feb; 34(2):95-6. PubMed ID: 11926565
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
    Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology and clinical relevance of proton pump inhibitors.
    Katz PO; Frissora C
    Curr Gastroenterol Rep; 2002 Dec; 4(6):459-62. PubMed ID: 12441035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.
    Orr WC; Harnish MJ
    Aliment Pharmacol Ther; 2003 Jun; 17(12):1553-8. PubMed ID: 12823159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.